Sara Gastoldi

Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome

Sara Gastoldi, Elena Bresin, Andrea Pasini, Beatrice Nardini et autres

INTRODUCTION: Atypical haemolytic uraemic syndrome (aHUS) is a rare and severe form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway, leading to sustained complement activation at the endothelial level and microvascular thrombosis, predominantly affecting the kidney. Anti-C5 therapy with …

it (code pays fourni par la source)

Complement-Mediated Postpartum Atypical Hemolytic Uremic Syndrome With Collapsing Focal Segmental Glomerulosclerosis Associated With a Novel CFHR5 Copy Number Variant

Rossella Piras, Carolina Martinatto, Elena Bresin, Marta Alberti et autres

Thrombotic microangiopathies (TMAs) that occur during pregnancy or the postpartum period-including preeclampsia/HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome (aHUS)-present a diagnostic challenge owing to their overlapping clinical features. We report a case of …

it (code pays fourni par la source)

Response to the Letter to the Editor Entitled “Defining “Dominance” in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation”

Sistiana Aiello, Donata Santarsiero, Sara Gastoldi, Ariela Benigni et autres

it (code pays fourni par la source)

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays

Donata Santarsiero, Sara Gastoldi, Valeria Guaschino, Elena Bresin et autres

Atypical hemolytic uremic syndrome (aHUS), or as recently suggested complement-mediated thrombotic microangiopathy,1 is primarily driven by genetic or acquired dysregulation of the alternative complement pathway (AP).2 Complement dysregulation results in persistent complement activation on cell surfaces, particularly targeting the endothelium, and leading …

it (code pays fourni par la source)

Dataset related to the article "Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays"

Donata Santarsiero, Sara Gastoldi, Valeria Guaschino, Elena Bresin et autres

The .pdf file contains raw data related to the article Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays. Kidney International Reports. 11 (3): 103717. doi: 10.1016/j.ekir.2025.103717.

it (code pays fourni par la source)

Dataset related to the article "Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays"

Donata Santarsiero, Sara Gastoldi, Valeria Guaschino, Elena Bresin et autres

The .pdf file contains raw data related to the article Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays. Kidney International Reports. 11 (3): 103717. doi: 10.1016/j.ekir.2025.103717.

it (code pays fourni par la source)

Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein

Anna Pezzotta, Alessandra Bovio, Barbara Imberti, Monica Locatelli et autres

Severe COVID-19 is characterized by thrombo-inflammatory processes within the lung microvasculature. In pursuit of effective treatments, clinical studies explored mesenchymal stromal cells (MSCs) as a promising approach due to their anti-inflammatory, immunomodulatory, and regenerative properties, through their paracrine action.Here, we tested the …

it (code pays fourni par la source)

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients

Valeria Guaschino, Donata Santarsiero, Sara Gastoldi, Joshua M. Thurman et autres

Atypical hemolytic uremic syndrome (aHUS) is a rare and severe thrombotic microangiopathy caused by genetic or acquired abnormalities leading to activation of the complement alternative pathway on cell surfaces. This process leads to endothelial dysfunction and microvascular thrombosis. The introduction of anti-C5 …

it, us (code pays fourni par la source)

Dataset related to the article "C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients"

Valeria Guaschino, Donata Santarsiero, Sara Gastoldi, Joshua Michael Thurman et autres

The .pdf file contains raw data related to the article C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients. Frontiers in Immunology. 2025; 16: 1620996. doi: 10.3389/fimmu.2025.1620996. Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare and severe thrombotic microangiopathy caused …

it, us (code pays fourni par la source)

Dataset related to the article "C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients"

Valeria Guaschino, Donata Santarsiero, Sara Gastoldi, Joshua Michael Thurman et autres

The .pdf file contains raw data related to the article C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients. Frontiers in Immunology. 2025; 16: 1620996. doi: 10.3389/fimmu.2025.1620996. Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare and severe thrombotic microangiopathy caused …

it, us (code pays fourni par la source)

Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome

Camillo Carrara, Blerina Mataj, Sara Gastoldi, Piero Ruggenenti et autres

Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition of small-vessel thrombosis with acute multiple-organ involvement and visceral damage. In this report, we present a case of a patient with CAPS who is refractory to conventional therapy. For the first time in a …

it (code pays fourni par la source)

Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy

Sistiana Aiello, Sara Gastoldi, Elena Bresin, Miriam Galbusera et autres

Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation. It may present as a recurrence of atypical hemolytic uremic syndrome (aHUS) or may occur de novo. 1 Kidney graft outcome in patients with recurrent aHUS is poor and strongly dependent on …

it (code pays fourni par la source)